Royalty Pharma (NASDAQ:RPRX) Lifted to “Buy” at StockNews.com
StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX – Free Report) from a hold rating to a buy rating in a report released on Tuesday. Several other research firms also recently weighed in on RPRX. Morgan Stanley raised their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an overweight rating in […]
20 Sep 08:20 · The Markets Daily